hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
Hvivo expects Continued Growth with Record Year in 2023
Hvivo, a pharmaceutical services company formerly known as Open Orphan, said it remained on track to hit its future growth targets after another record year in 2023. The company is set to begin paying annual dividends,